Growth Metrics

Novavax (NVAX) Current Assets (2016 - 2025)

Historic Current Assets for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $974.6 million.

  • Novavax's Current Assets fell 1169.63% to $974.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $974.6 million, marking a year-over-year decrease of 1169.63%. This contributed to the annual value of $1.1 billion for FY2024, which is 130.66% down from last year.
  • Latest data reveals that Novavax reported Current Assets of $974.6 million as of Q3 2025, which was down 1169.63% from $919.5 million recorded in Q2 2025.
  • Novavax's 5-year Current Assets high stood at $2.4 billion for Q2 2021, and its period low was $727.1 million during Q1 2024.
  • Moreover, its 5-year median value for Current Assets was $1.1 billion (2023), whereas its average is $1.5 billion.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 78029.09% in 2021, then plummeted by 5863.4% in 2023.
  • Quarter analysis of 5 years shows Novavax's Current Assets stood at $2.2 billion in 2021, then decreased by 20.96% to $1.7 billion in 2022, then crashed by 32.85% to $1.1 billion in 2023, then decreased by 1.31% to $1.1 billion in 2024, then fell by 13.67% to $974.6 million in 2025.
  • Its Current Assets stands at $974.6 million for Q3 2025, versus $919.5 million for Q2 2025 and $868.0 million for Q1 2025.